2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings.

Innovent presents clinical data for bispecific fusion protein IBI363

Innovent Biologics released updated clinical trial metrics at ESMO 2026 for IBI363/TAK-928, a bispecific fusion protein engineered to treat advanced solid malignancies.